NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a collaboration with Mayo Clinic to support a research program evaluating a novel treatment for pediatric diffuse midline glioma (DMG), an aggressive childhood brain cancer. The program is funded by a grant from the Children's Cancer Research Fund (CCRF) awarded to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
The research aims to address a key challenge in treating malignant brain tumors: achieving and maintaining therapeutic drug concentrations within the tumor. While convection-enhanced delivery (CED) allows drugs to bypass the blood-brain barrier through direct intracranial infusion, therapeutic benefit can be limited by rapid drug clearance from the treatment site. The Mayo Clinic team will evaluate a combination therapy strategy to enhance intratumoral drug retention by modulating drug efflux mechanisms, with the goal of prolonging therapeutic exposure after localized delivery. The project will begin with large animal studies and may expand to human studies if successful.
The study will use NeuroOne's investigational drug delivery neural device technology, which combines precision intracranial drug delivery with simultaneous neural recording. This integrated approach aims to enable targeted therapy while providing real-time physiologic monitoring throughout treatment, offering insight into drug delivery and effects on the surrounding neural environment. The CCRF award marks a milestone in advancing this therapeutic approach toward clinical evaluation and reflects growing interest from academic investigators and biopharmaceutical companies in NeuroOne's drug delivery platform.
David Wambeke, Chief Business Officer of NeuroOne, stated, 'This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform. We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording. We are honored to support Mayo Clinic's efforts to develop new treatment options for children facing these devastating brain tumors.'
NeuroOne, based in Eden Prairie, Minnesota, focuses on improving surgical care for neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgeries, lower costs, and improve outcomes. The company is also engaged in R&D for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
For more information, visit nmtc1.com. This collaboration underscores the potential of NeuroOne's technology to address critical challenges in treating brain tumors, particularly for pediatric patients with limited options. The integration of drug delivery and neural monitoring could provide real-time feedback, potentially improving treatment efficacy and safety. As the program progresses, successful outcomes could pave the way for new standards in targeted intracranial therapies.
